Material science advances have reshaped the design and performance of cardiac stents, small mesh tubes implanted in coronary arteries to restore blood flow in patients with atherosclerosis. The dual requirement for flexibility—to navigate tortuous vessels and conform to arterial motion—and structural strength—to resist recoil and maintain luminal patency—has driven decades of innovation in alloys, polymers, and surface treatments. This article examines the key material breakthroughs that have improved stent flexibility and strength, the clinical benefits these advances bring, and the emerging technologies poised to define the next generation of coronary scaffolds.

The Mechanics of Stent Function: Balancing Flexibility and Strength

A cardiac stent must compress to a small diameter for delivery via catheter, expand at the target lesion, and then support the artery wall against chronic outward forces and repetitive cardiac contraction. Flexibility during delivery reduces vessel trauma and allows access to distal or calcified lesions. Once deployed, the stent must exhibit sufficient radial strength to resist elastic recoil and maintain diameter. These two properties often compete: a stent with thicker struts or a denser mesh may be strong but stiff, while a very flexible design may lack the durability needed for long-term patency. Material science addresses this tension by selecting alloys and engineering geometries that optimize both characteristics simultaneously.

Historical Material Evolution: From Stainless Steel to Advanced Alloys

Early coronary stents, such as the Palmaz-Schatz design of the late 1980s, were constructed from 316L stainless steel. While stainless steel offered adequate strength and radiopacity, its relatively high modulus of elasticity resulted in a stiff device that could be difficult to deliver through calcified or tortuous arteries. Moreover, the material’s corrosion resistance was satisfactory, but its ferromagnetic properties complicated MRI follow-up. The search for alternatives led to the adoption of cobalt-chromium (Co-Cr) alloys and later to nickel-titanium (Nitinol) shape-memory alloys.

Stainless Steel Limitations

Stainless steel stents typically employed strut thicknesses of 100–140 µm. Thicker struts increase radial strength but also elevate the risk of restenosis due to greater vessel wall injury and delayed endothelialisation. The stiffness also made these stents prone to longitudinal deformation during deployment or when subjected to external compression. Despite these drawbacks, stainless steel remained the standard bearer until the early 2000s, when improvements in metallurgy and manufacturing enabled thinner-strut designs.

Cobalt-Chromium Breakthrough

Cobalt-chromium alloys, such as L605 and MP35N, entered the market in the mid-2000s. Their tensile strength (up to 1000 MPa) is roughly 2.5 times that of 316L stainless steel, allowing manufacturers to reduce strut thickness to 60–80 µm while maintaining equivalent or superior radial strength. Thinner struts reduce vessel injury, lower the inflammatory response, and accelerate re-endothelialisation. In addition, Co-Cr stents exhibit excellent radiopacity due to the high atomic number of cobalt, improving visibility under fluoroscopy. The alloy’s work-hardening characteristics also support advanced stent patterns—such as helical or sinusoidal rings—that enhance flexibility without sacrificing structural integrity. Major clinical trials have confirmed that Co-Cr drug-eluting stents (DES) achieve low rates of target lesion revascularisation and stent thrombosis.

Nitinol and Shape Memory

Nitinol, an equiatomic alloy of nickel and titanium, possesses two unique properties: superelasticity and shape memory. Superelasticity allows the material to undergo large deformations (up to 8% strain) and return to its original shape upon unloading, a tenfold improvement over stainless steel. This property is invaluable for self-expanding stents used in carotid, peripheral, and certain coronary applications. For coronary use, nitinol-based stents can be crimped to a very low profile and then expand to a preset diameter when exposed to body temperature. The low elastic modulus of nitinol (about 40 GPa, compared to 200 GPa for steel) translates into a flexibility that closely matches arterial compliance, reducing vessel straightening and edge dissection. However, concerns about nickel ion release and long-term corrosion have led to surface-modification strategies, such as oxide formation or polymer coatings, to improve biocompatibility.

Polymer and Bioresorbable Stents: The Next Frontier

While metallic stents remain the clinical standard, polymer-based and fully bioresorbable scaffolds (BRS) have emerged as alternatives aimed at eliminating the permanent foreign body and reducing long-term adverse events. Early polymeric stents made from poly-L-lactic acid (PLLA) faced challenges in both strength and flexibility. Newer formulations, including blends with polycaprolactone and magnesium-reinforced composites, have improved mechanical performance.

Drug-Eluting Stents and Polymer Coatings

Modernday drug-eluting stents combine a metallic platform with a polymer coating that releases an antiproliferative drug (e.g., everolimus, zotarolimus) to inhibit neointimal hyperplasia. The polymer must be biocompatible and durable enough to control drug release over several weeks, yet flexible enough not to crack or delaminate during stent expansion. Early efforts used non-erodible polymers (e.g., polyethylene-co-vinyl acetate, poly-n-butyl methacrylate), but these were associated with chronic inflammation and delayed healing. This motivated the development of biodegradable polymer coatings, such as those based on poly-D,L-lactide or poly(lactide-co-glycolide) (PLGA), which resorb within 6–12 months, leaving a bare metal surface. The switch to thinner, more compliant polymer layers has improved deliverability and reduced the risk of stent thrombosis associated with polymer remnants.

Fully Bioresorbable Scaffolds

Fully bioresorbable scaffolds (BRS) are designed to provide temporary mechanical support and then dissolve completely, potentially restoring vascular vasomotion and avoiding late stent failure. The most studied BRS is the Absorb BVS (Abbott), which used a PLLA backbone with a poly(D,L-lactide) coating eluting everolimus. Initial trials showed promising results at one year, but later data indicated higher rates of device thrombosis compared to metallic DES, attributed partly to thicker struts (150 µm) and inadequate mechanical strength. Newer BRS designs employ different materials: magnesium scaffolds offer higher radial strength and faster resorption, while composite materials incorporating nano-hydroxyapatite or carbon-fibres aim to balance strength with flexibility. For instance, the Magmaris magnesium scaffold (Biotronik) uses a silicon-oxynitride coating to slow corrosion and has demonstrated improved clinical outcomes at 12 months. Research continues to optimise strut geometry and degradation profiles to match the healing timeline of the vessel wall.

Emerging Technologies: Nanomaterials and Surface Engineering

Nanotechnology is being applied at multiple levels to enhance stent performance. Surface modifications, such as the deposition of nanostructured titanium dioxide or silicon carbide layers, improve endothelial cell adhesion while reducing platelet aggregation and neointimal hyperplasia. Nanoporous coatings can serve as reservoirs for drug loading, allowing controlled release without a polymeric carrier, thereby eliminating polymer-related complications. Carbon-based coatings (diamond-like carbon, carbon nanotubes) offer low friction and high hardness, potentially reducing thrombogenicity. In the bulk material domain, the incorporation of nanoparticles into metallic or polymeric matrices can increase strength and fracture toughness. For example, magnesium alloys reinforced with nano-sized yttrium oxide particles show improved corrosion resistance and mechanical integrity. These approaches remain largely experimental but hold promise for stents that are not only stronger and more flexible but also actively promote vascular healing.

Clinical Impact and Patient Outcomes

The material advances described have translated into measurable improvements in percutaneous coronary intervention outcomes. Thinner-strut cobalt-chromium DES have reduced restenosis rates to below 5% in simple lesions and have enabled treatment of complex anatomies (bifurcations, chronic total occlusions, multivessel disease) with lower complication rates. Nitinol self-expanding stents are now standard for carotid artery stenting and have expanded the treatable population for peripheral artery disease. Bioresorbable scaffolds, while still evolving, offer the theoretical advantage of leaving no permanent implant, reducing the need for long-term dual antiplatelet therapy in selected patients. Registry data suggest that newer-generation DES with biodegradable polymers achieve very low rates of stent thrombosis (less than 0.5% per year) and maintain patency for extended follow-up periods. The improved flexibility of modern stents has also reduced delivery failure rates, shortened procedure times, and improved the ability to treat vessels with extreme tortuosity or calcification.

Future Research Directions

Ongoing investigation aims to push the boundaries of stent material science further. Key areas include: (1) Shape-memory polymers that can be triggered by body temperature or external stimuli to change geometry or deliver drugs at targeted sites; (2) Self-healing coatings that repair microscopic cracks or abrasions, prolonging device durability; (3) 3D-printed stents customised to patient-specific anatomy using alloys or polymers, potentially optimising both flexibility and strength at the lesion level; and (4) Smart stents with integrated sensors to monitor local haemodynamics or drug release. The role of computational modelling (finite element analysis) is also expanding, enabling virtual testing of new material-strut geometry combinations before physical prototyping. As these technologies mature, the goal of a stent that is not only strong and flexible but also intelligent and truly biocompatible moves closer to reality.

For further reading on stent material innovations, consult the review article in Frontiers in Bioengineering and Biotechnology, the clinical overview on stent materials, and the FDA summary of approved coronary stent devices.